Biochemical and haematological variables in vegetarians
Relatively little is known about the long-term consequences of a vegetarian diet. Vegetarians have lower serum cholesterol concentrations than non-vegetarians' and Seventh-Day Adventists in the United States of America appear to have a lower prevalence of ischaemic heart disease than the general population.2 On the other hand, vegetarian diets may be associated with impaired calcium absorption and with anaemia. We have recently measured various biochemical and haematological variables in two groups of vegetarians and a group of non-vegetarians.
Subjects, methods, and results
The subjects studied were (1) 56 vegetarians and 264 non-vegetarians who were volunteers in an epidemiological study which suggested a protective role of cereal fibre in diverticular disease,3 and (2) a further group of 35 vegetarians attending a vegetarian congress at Guildford in the summer of 1978. The volunteers were all aged between 30 and 69 years and the groups comprised roughly equal numbers of men and women. Fasting plasma lipid, lipoprotein, cholesterol, and glucose concentrations were measured by methods we have previously described.4 The other variables (see table) were measured in the clinical biochemistry laboratory of the Radcliffe Infirmary, Oxford. All measurements were made without knowledge of whether the samples were from vegetarians or non-vegetarians. The significance of differences between groups was assessed by means of the unpaired t test.
Selected results are shown in the table. Analyses of the diet histories suggested that the difference in cholesterol concentrations might be because of a difference in saturated fat intake rather than because vegetarians had a higher intake of dietary fibre. Vegetarians with a saturated and monounsaturated fat intake of over 50 g daily had a mean plasma cholesterol concentration of 6 2 mmol/l (239 mg/100 ml), which is similar to that in non-vegetarians. No relationship was apparent between cholesterol and dietary fibre. The differences in blood glucose and high density lipoprotein (HDL) expressed as a percentage of total cholesterol were small but consistent and statistically significant. Despite calcium and haemoglobin concentrations being lower in vegetarians none were anaemic: the lowest calcium concentration was 2 21 mmol/l (8 8 mg/l00 ml). None of the differences between groups could be explained by differences in age and sex. The 35 vegetarians in group 2 were studied in the summer, whereas the vegetarians and non-vegetarians in group 1 were studied over the course of a year. Numbers were too few to examine for seasonal variation in detail, but there were no appreciable differences between the two groups. Relevant Coneversion: SI to traditional units Blood glucose: 1 mmol I-18 mg 100 ml. Plasma cholesterol: 1 mmol,l _ 38 6 mg 100 ml. Plasma triglyceride: 1 mmol I 88 5 nmg 100 ml. Blood urea: 1 mmol 1 z 6-0 mg 100 ml. Plasma uric acid: 1 mmol 1 16 8 mg 100 ml.
Plasma calcium: 1 mmol 1_ 4-0 mg 100 msl. Miean cell vol (M1CV): 1 fl= 1 .lm.
Comment
The vegetarians studied were all members of the Vegetarian Society of the United Kingdom and consequently not necessarily representative of all vegetarians. The data are nevertheless of interest, and some of the differences may explain at least in part the low prevalence of ischaemic heart disease in the largely vegetarian SeventhDay Adventists.2 The data confirm the need foralong-term prospective study of vegetarians, whose indicators of carbohydrate and lipid metabolism (including the ratio of HDL to total cholesterol5) seem to be more favourable to health than those of non-vegetarians. Interaction between carbamazepine and warfarin Several anticonvulsants increase the rate of metabolism of warfarin and reduce its hypoprothrombinaemic effect. This is due to induction of hepatic microsomal enzymes.1 2 Carbamazepine induces microsomal enzymes in man and shortens the plasma half life of warfarin, lowers serum warfarin concentrations, and reduces the hypoprothrombinaemic effect under controlled conditions.3 We know of no reports of this interaction occurring during the routine management of patients on anticoagulants. We describe a patient on warfarin in whom discontinuing carbamazepine resulted in a potentially dangerous increase in prothrombin time.
Case report
A 56-year-old man had been taking warfarin since he had an aortic valve prosthesis inserted five years before. He had been taking carbamazepine 300-600 mg daily for 15 months for trigeminal neuralgia and his prothrombin 20-; 2 a
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time had been stable in the therapeutic range (two to three times control) taking 6 mg warfarin daily. He discontinued his carbamazepine, and when seen four weeks later his prothrombin time was five times control. He subsequently required 4 mg warfarin daily to maintain his prothrombin time at two to three times control. Some months later he started taking carbamazepine 300 mg daily again. The prothrombin time was measured weekly and his warfarin dose adjusted as necessary. His serum y-glutamyl-transferase (y-GT) concentration was also measured weekly. His warfarin requirements increased from 3-5 mg daily to 5 5 mg daily over a period of five weeks and his serum y-GT rose from 11 U/I to 27 U/l during the same period. The effects of carbamazepine on warfarin dose and y-GT are shown in the figure.
Comment
Stopping carbamazepine considerably increased the effect of warfarin on the prothrombin time in this patient and restarting carbamazepine reduced the effect of warfarin, taking five weeks to reach a steady state. Hansen et al showed that giving carbamazepine to patients already taking warfarin lowered serum warfarin concentrations and warfarin half life.3 Warfarin is hydroxylated by hepatic microsomal enzymes,3 and Whitfield et a14 showed that changes in y-GT may reflect changes in the activity of liver cell microsomal enzymes. The results in our patient suggest that this interaction may be clinically important and is probably due to increased warfarin metabolism produced by carbamazepine. While occasionally there may be radiological evidence of osteomalacia in rheumatoid arthritis' and histological osteomalacia may be found in some patients with rheumatoid arthritis and bone pain,2 the exact state of vitamin D metabolism in this disease remains uncertain. In a recent series of 23 patients with rheumatoid arthritis there was no biochemical evidence of osteomalacia and serum 25-hydroxy vitamin D (25-OHD) concentrations were within the normal range.3 Since serum 25-OHD concentrations can be affected by medication and lack of sunlight exposure owing to immobility, we have compared the concentrations in 30 patients with rheumatoid arthritis and 30 patients with osteoarthrosis, all sufficiently severe to be admitted to hospital, to show any alterations caused by rheumatoid arthritis. 
Since the 25-OHD concentrations were measured in winter before the patients had been exposed to a hospital diet or fluorescent light their plasma 25-OHD was probably at its lowest annual value and osteomalacia at its most obvious. The two groups were well matched for all factors that might have altered vitamin D metabolism, apart from the type of arthritis. Nevertheless, there was no significant difference in their 25-OHD concentrations and the mean value in the rheumatoid arthritis patients was similar to that recently reported (68 7 mmol/l) by Kennedy et al.3 We have found no evidence of biochemical osteomalacia in rheumatoid disease, and although osteomalacia may occasionally occur it probably does so coincidentally. 25-OHD concentrations fell with age in both groups, as they would in a normal population. The possible association between 25-OHD and ESR in rheumatoid disease deserves further study, though we have found no evidence that systemic 25-OHD concentrations relate to the degree of juxtaarticular osteopenia that differentiates rheumatoid arthritis from osteoarthrosis.
